Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488538 | 0.91 | MET (0.54) | METPTGER1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL17224826 | 0.87 | MET (0.45) | METPTGER1HTTKMT2ARAB9A | |
| SCHEMBL488676 | 0.85 | MET (0.55) | METHTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL26917099 | 0.84 | DHFR (0.49) | METHTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL29857940 | 0.84 | DHFR (0.49) | METHTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL488799 | 0.82 | MET (0.64) | METHTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL15663813 | 0.82 | MET (0.50) | METPTGER1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL15812284 | 0.82 | MET (0.44) | METPTGER1DHFRDCPSALOX5AP | |
| SCHEMBL18573923 | 0.82 | MET (0.44) | METKMT2ARAB9ASMN1; SMN2MAPK14 | |
| SCHEMBL488716 | 0.80 | DHFR (0.39) | METHTTKMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-26 | — | — | US | disclosed |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-26 | — | — | US | disclosed |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-15 | — | — | US | disclosed |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-15 | — | — | US | disclosed |
| EP-3227287-B1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3227287-B1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| US-20180319794-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-08 | — | — | US | disclosed |
| US-10052312-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-21 | — | — | US | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10052312-B2 | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAICS | MET 3265/4885PTGER1 280/4885HTT 4068/4885 |
| US-20190248783-A9 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PAICS | MET 3265/4885PTGER1 280/4885HTT 4068/4885 |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | AADAC, TNNI3, TNNT2 | MET 3349/4885PTGER1 81/4885HTT 4556/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | MET 1/4885PTGER1 301/4885HTT 4453/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | MET 1/4885PTGER1 919/4885HTT 4481/4885 |
| US-20180319794-A1 | AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PAICS | MET 3265/4885PTGER1 280/4885HTT 4068/4885 |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | TNNI3, CYP11B2, PPIP5K2 | MET 3014/4885PTGER1 259/4885HTT 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.